AP
MLYS icon

Andera Partners’s Mineralys Therapeutics MLYS Stock Holding History

Andera Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.1M Hold
1,591,917
– – 24.38% 3
2025
Q4 		$57.8M Buy
+1,591,917
New +$63.8M 32.71% 2

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Andera Partners's MLYS Position: Q1 2026 in Review

Andera Partners held its Mineralys Therapeutics (MLYS) position steady in Q1 2026 at 1,591,917 shares worth $43.1M. The position accounts for 24.38% of the portfolio, ranked #3.

Andera Partners first reported a position in MLYS in Q4 2025 and has held it in 2 quarters since. The position peaked at $57.8M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Andera Partners held 1,591,917 shares of Mineralys Therapeutics worth $43.1M as of Q1 2026.
  • Andera Partners left its Mineralys Therapeutics share count unchanged in Q1 2026.
  • Mineralys Therapeutics made up 24.38% of Andera Partners's portfolio in Q1 2026, its #3 holding.
  • Andera Partners first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Andera Partners's Mineralys Therapeutics position peaked at $57.8M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Andera Partners's 13F filing for Q1 2026, filed 11 May 2026.